From: Targeting the PDGF signaling pathway in tumor treatment
Tumor type | Results of patient studies | Refs |
---|---|---|
Glioblastoma multifome | Only limited effects of single agent treatment by imatinib in Phase II and Phase III studies. | |
No significant effect of imatinib treatment in combination with hydroxyurea. | ||
Chordoma | 1 PR and 35 SD out of 50 patients treated, were observed in a Phase II study. | [110] |
Meningeoma | No or only modest effect of imatinib as single agent or combined with hydroxyurea. | |
Among 9 patients preselected for PDGFR expression, 7 SD were noted. | [113] | |
Dermatofibrosarcoma protuberance | In a Phase II study, 4 CR and 4 PR out of 12 patients treated were recorded. | [126] |
In other Phase II trials, PR was noticed in about half of the patients. | ||
Gastrointestinal stromal tumor | Imatinib and other tyrosine kinase inhibitors against PDGFRα and Kit are used routinely in the clinic with good results | |
Soft tissue sarcoma | In a Phase III study with 369 patients a median progression-free survival of 4.6Â months was noted in patients treated with pazopanib compared with 1.6Â months for untreated controls | [149] |
Osteosarcoma | No advantage of treatment with imatinib as single agent. | [141] |
Some effect of imatinib in combination with everolimus in treatment of synovial sarcoma. | [142] | |
Chronic myeloproliferative diseases | Patients with CMML with rearrangement of PDGFRβ responded to imatinib. | [168] |
Hypereosinophilic syndrome | Patients with HES responded to imatinib. | |
Patients who developed resistance to imatinib responded to nilotinib or sorafenib. | ||
Prostate cancer | Out of 44 patients with hormone-refractory prostate cancer treated with sunitinib, 1 had PR, 3 a decline in prostate specific antigen of >50%, and 9 had a significant improvement in pain. | [181] |
No increased survival upon treatment with imatinib. | ||
Non-small cell lung cancer | Combination treatment with imatinib and docetaxel yielded 1 PR and 4 SD out of 20 treated patients. | [213] |
2 PR and 7 SD were observed after treatment of 18 patients with sunitinib. | [214] | |
Neuroblastoma | Little or no effect by imatinib as single agent treatment of children with relapsed or refractory neuroblastoma. | [236] |